Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Core Viewpoint - Hoth Therapeutics has reported positive preclinical safety data for its investigational oncology candidate HT-KIT, demonstrating dose-dependent liver activity with no observed toxicity, which is a significant milestone as the company prepares for an Investigational New Drug (IND) filing [1][2][4]. Preclinical Findings - The study showed a clear dose-responsive effect on liver mass, with liver weight increasing from 1.11g at 0 mg/kg to 1.32g at 3.0 mg/kg, indicating pharmacological engagement [7][8]. - No adverse effects were observed on the kidney, spleen, or thymus, confirming a 100% clean safety profile with no visible lesions or gross pathology in any treated animal [7][8]. - The favorable safety profile of HT-KIT supports the company's plans to advance to Good Laboratory Practice (GLP) studies and submit an IND application soon [4][3]. Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare and inflammatory diseases, aiming to improve patient quality of life through early-stage pharmaceutical research and development [5].